Frank Ruffo's Insider Trades & SAST Disclosures
Frank Ruffo's most recent trade in Aclaris Therapeutics Inc was a trade of 12,823 Common Stock done at an average price of $15.5 . Disclosure was reported to the exchange on March 10, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Frank Ruffo.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.55 per share. | 10 Mar 2022 | 12,823 | 201,883 (0%) | 0% | 15.5 | 199,335 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 155,200 | 155,200 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 44,300 | 44,300 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 25,750 | 25,750 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 25,750 | 198,109 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 8,300 | 24,900 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 8,300 | 206,409 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 8,297 | 16,595 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2022 | 8,297 | 214,706 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 3,875 | 173,747 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2022 | 3,875 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 33,189 | 184,909 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 33,189 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.51 per share. | 01 Jun 2021 | 12,587 | 172,322 (0%) | 0% | 21.5 | 270,748 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.30 per share. | 01 Jun 2021 | 2,450 | 169,872 (0%) | 0% | 22.3 | 54,635 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.84 per share. | 22 Apr 2021 | 30,000 | 209,059 (0%) | 0% | 26.8 | 805,218 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.64 per share. | 22 Apr 2021 | 29,200 | 179,859 (0%) | 0% | 26.6 | 777,797 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.79 per share. | 22 Apr 2021 | 27,239 | 151,820 (0%) | 0% | 25.8 | 702,584 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.33 per share. | 22 Apr 2021 | 800 | 179,059 (0%) | 0% | 27.3 | 21,863 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.44 per share. | 22 Apr 2021 | 100 | 151,720 (0%) | 0% | 26.4 | 2,644 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 116,000 | 116,000 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 33,200 | 33,200 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 25,750 | 51,500 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 25,750 | 240,939 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 8,297 | 24,892 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 8,297 | 241,903 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.06 per share. | 01 Mar 2021 | 7,333 | 233,606 (0%) | 0% | 24.1 | 176,432 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.25 per share. | 01 Mar 2021 | 2,844 | 239,059 (0%) | 0% | 23.3 | 66,123 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 3,875 | 3,875 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 3,875 | 216,497 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 21.35 per share. | 01 Feb 2021 | 1,308 | 215,189 (0%) | 0% | 21.4 | 27,926 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 1,300 | 212,992 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 1,300 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.59 per share. | 15 Dec 2020 | 370 | 212,622 (0%) | 0% | 4.6 | 1,698 | Common Stock |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2020 | 33,188 | 33,189 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2020 | 33,188 | 221,143 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | Frank Ruffo | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.32 per share. | 01 Jun 2020 | 9,451 | 211,692 (0%) | 0% | 1.3 | 12,475 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges